Cognition Therapeutics’ (CGTX) “Buy” Rating Reaffirmed at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Cognition Therapeutics (NASDAQ:CGTX) in a report released on Wednesday morning,Benzinga reports. The brokerage currently has a $11.00 target price on the stock.

A number of other analysts have also commented on CGTX. B. Riley upgraded Cognition Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $1.00 to $1.50 in a research report on Thursday, December 19th. Brookline Capital Management upgraded shares of Cognition Therapeutics to a “strong-buy” rating in a research report on Monday, January 27th. Finally, HC Wainwright increased their price objective on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a report on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $8.30.

Cognition Therapeutics Stock Performance

NASDAQ CGTX opened at $0.50 on Wednesday. The stock has a market capitalization of $20.57 million, a P/E ratio of -0.51 and a beta of 0.96. Cognition Therapeutics has a 52 week low of $0.34 and a 52 week high of $2.95. The stock has a fifty day moving average of $0.68 and a 200-day moving average of $0.58.

Institutional Trading of Cognition Therapeutics

Hedge funds have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in Cognition Therapeutics during the fourth quarter valued at approximately $26,000. Virtu Financial LLC bought a new position in shares of Cognition Therapeutics during the third quarter worth $27,000. Two Sigma Investments LP grew its holdings in shares of Cognition Therapeutics by 372.2% in the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock valued at $38,000 after buying an additional 42,321 shares during the period. Sigma Planning Corp increased its position in shares of Cognition Therapeutics by 14.6% in the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after buying an additional 25,050 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Cognition Therapeutics by 8.9% during the 4th quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock worth $247,000 after buying an additional 28,705 shares during the period. 43.35% of the stock is currently owned by institutional investors and hedge funds.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.